Canada (English) 
Denmark 
Finland 
France 
Germany 
Italy 
Japan 
Norway 
Spain 
Sweden 
United Kingdom 
Global 
About Us
A smallbiotechcompanybuilt on abig dream
A history of taking on challenges
A biotech company with a history as long as ours is rich in ups and downs. Learnings and insights. Failures and successes. Throughout our existence, we have always stayed true to our core commitment to discover, develop, and deliver treatments to patients that may have an extraordinary impact on their lives.
We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe.
BioCryst through the years
Leading by example
Flexible, transparent, and human. Just a few words to describe our leadership team, whose members are dedicated to bringing out the best in our people. Get to know them-and how they enable us to move quickly to achieve the mission at hand.
Chief People Officer
Chief People Officer
About Stephanie
Stephanie joined BioCryst in November 2018 from Russell Reynolds Associates, an executive search firm, where she was a consultant in the Human Resources practice in New York City.
Previously, Stephanie was the senior HR business partner for the Consumer & Content brands business at AOL (now Oath) and held various Human Resources leadership roles at TIAA. Prior to that, she spent nearly 10 years at Bank of America Merrill Lynch in various Human Resources roles supporting the corporate and investment bank in Charlotte, Hong Kong, and New York. Stephanie holds a B.A., with honors, in public and interpersonal communications from North Carolina State University.
Chief Discovery Officer
Chief Discovery Officer
About Yarlagadda
Dr. Babu directs a team of structural biologists, medicinal chemists, and research biologists while overseeing the structure-based drug discovery program at the BioCryst Discovery Center of Excellence in Birmingham, Alabama. Dr. Babu joined the company in 1988 as the company’s first full-time employee. Prior to that, he served 5 years on the biochemistry faculty at the University of Alabama at Birmingham (UAB). He obtained his Ph.D. from the Indian Institute of Science, Bangalore, and spent 3 years in the Laboratory of Molecular Biophysics at the University of Oxford, United Kingdom, before joining UAB. Dr. Babu has over 70 scientific publications in peer-reviewed journals, and a number of issued and pending patents to his credit.
Chief Legal Officer
Chief Legal Officer
About Alane
As a member of the core leadership team, Alane Barnes is Chief Legal Officer for BioCryst. Ms. Barnes is responsible for all aspects of the company’s legal affairs. Prior to BioCryst, she served at the University of Alabama at Birmingham, managing its intellectual property and license negotiations. Ms. Barnes began her legal career practicing transactional, life science, and general corporate law at Berkowitz, Lefkovits, Isom & Kushner in Birmingham, Alabama. She graduated magna cum laude from Cumberland School of Law in 1997, and is a member of Curia Honoris, Scholar of Merit. She served on the board of the Biotechnology Association of Alabama and as a mentor for Alabama Launchpad, a competition created to fuel the development of companies in Alabama. Ms. Barnes is currently a Board Member and the Vice President of the Research Triangle Area Association of Corporate Counsel and is a regular speaker at national conferences regarding the pharmaceutical business and women’s success in business. She is a 2010 graduate of MOMENTUM, an organization geared toward building leadership in women.
Chief Communications Officer
Chief Communications Officer
About John
John Bluth joined BioCryst in April 2019 and is a member of the core leadership team. Prior to BioCryst, Mr. Bluth led IR and Corporate Communications for US and international-based life sciences and clean technology companies, including Cempra, which merged with Melinta Therapeutics in 2017, and two of Silicon Valley’s leading biotechnology companies, CV Therapeutics, which was acquired in 2009, and Aviron, acquired in 2002. Before joining Aviron, he led the west coast healthcare practice for Fleishman Hillard, an international public relations firm. From 2009 to 2012, he led IR and Group Communications at German-based Elster Group, one of the world’s largest electricity, gas, and water measurement and control providers. From 2012 to 2016, Mr. Bluth led IR and Corporate Communications for PowerSecure International, Inc., a leading provider of energy technologies and services to electric utilities and their large industrial, commercial, institutional, and municipal customers. PowerSecure was acquired in May 2016. Mr. Bluth holds a Bachelor’s degree in physiology from Cornell University.
Chief Financial Officer
Chief Financial Officer
About Anthony
Anthony Doyle joined BioCryst as Chief Financial Officer in April 2020. Prior to joining BioCryst, he served as Chief Financial Officer of Worldwide Clinical Trials, a full-service global contract research organization, beginning in 2014. From 2004 to 2012, Mr. Doyle held roles of increasing responsibility at General Electric (GE), moving through FP&A, controller, audit, tax, and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs, leading risk and pricing for GE Healthcare’s $1.2 billion US diagnostic imaging business, and serving as Global Program Manager for GE Healthcare Solutions, a hospital and healthcare outcomes–based consulting company. From 2012 to 2014, he was Chief Financial Officer of World Book, a Berkshire Hathaway company. He received his B.A. from Dublin City University (Ireland) and his DESEM from Reims Management School (France).
Chief Business Development Officer
Chief Business Development Officer
About Clayton
Clayton Fletcher was appointed Chief Business Development Officer of BioCryst in January 2023. In this role, Mr. Fletcher is responsible for leading business development activities, identifying potential strategic partnerships, and licensing and M&A activities for the company.
Mr. Fletcher joined BioCryst with over 25 years of business development experience in the biopharmaceutical industry. He previously served as Senior Vice President of Business Development & Strategic Planning at Idera Pharmaceuticals, Inc. where he was responsible for evaluation and execution of business development activities including valuation, due diligence, licensing, acquisition, and contract negotiation. Mr. Fletcher served as Vice President of Business Development & Project Management at ViroPharma Inc. overseeing the acquisition of Cinryze (LEV Pharmaceuticals). Prior to joining ViroPharma, Mr. Fletcher held multiple roles of escalating responsibility at SmithKline Beecham Pharmaceuticals/GlaxoSmithKline, Becton-Dickinson and Company, Zynaxis Inc./Intracell Corporation, and Centocor Corporation. Mr. Fletcher received B.S. and M.S. degrees in biology from Wake Forest University in 1985 and 1990, respectively.
Chief Commercial Officer
Chief Commercial Officer
About Charlie
Charlie Gayer joined BioCryst in August 2015 as Vice President of Global Strategic Marketing and was promoted to Chief Commercial Officer in January 2020. Prior to joining BioCryst, Mr. Gayer held several US and global commercial leadership roles in competitive rare disease categories at Talecris. He led US alpha-1 antitrypsin deficiency marketing and later European sales and marketing. After Grifols acquired Talecris in 2011, he led the US marketing team for the combined immune globulin portfolio of the 2 companies. Prior to joining Talecris, Mr. Gayer spent 6 years at GlaxoSmithKline in a range of professional marketing, consumer marketing, and sales roles. Mr. Gayer began his career as a strategic consult for biopharmaceutical companies and also spent 3 years as a business analyst at rare disease pioneer Genzyme Corporation. Mr. Gayer received his B.A. in politics from Princeton University and his M.B.A. from the Fuqua School of Business of Duke University.
Chief Strategy Officer
Chief Strategy Officer
About Philip
Philip George was appointed Chief Strategy Officer of BioCryst in September 2022. In this role, Mr. George is responsible for overseeing the development, communication and execution of the long-term strategy for the company.
Mr. George joined BioCryst with more than 30 years of experience in management consulting, working with approximately 30 different healthcare companies over the course of his career. He began his consulting career at Accenture (formally Andersen Consulting) in 1991, where he provided strategy and operational counsel to companies in the biopharmaceutical industry. While at Accenture, Mr. George held roles of increasing responsibility, including leading the firm’s North American Pharmaceutical and Medical Products strategy group. Following his time at Accenture, he has served as an independent consultant, focusing almost exclusively on working with early- to mid-stage biopharma companies.
Mr. George received his B.Sc from the University of Bristol and his M.B.A. from London Business School in the United Kingdom.
Chief Regulatory Officer
Chief Regulatory Officer
About Salisa
Salisa Hauptmann joined BioCryst in January 2021 as Senior Vice President, Global Regulatory Affairs and Medical Writing, and was promoted to Chief Regulatory Officer in June 2023. Prior to joining BioCryst, Ms. Hauptmann held roles of increasing levels of responsibility in the regulatory and compliance functions at multiple companies including GlaxoSmithKline, Stiefel Laboratories, Novartis, and most recently, Merz Pharmaceuticals. With over 20 years of experience in the biopharmaceutical industry, Ms. Hauptmann has in-depth global expertise in the development and commercialization of drugs and biologics in numerous therapeutic areas and extensive regulatory experience in emerging markets. Throughout her career, Ms. Hauptmann has built functions and led numerous organizational optimization efforts focused on operational excellence, optimization of processes, and implementing Regulatory Operations IT system solutions while maintaining the highest level of compliance.
Ms. Hauptmann holds a B.A. in History from the University of California, Davis, and a Master’s Degree in Public Health Administration (MPH) from Webster University in St. Louis.
Chief Data and Insights Officer
Chief Data and Insights Officer
About Jinky
Jinky Rosselli was appointed Chief Data and Insights Officer of BioCryst in November 2021. In this role, Ms. Rosselli oversees a global team responsible for BioCryst’s data science, analytics, and insights infrastructure, helping inform and guide strategic decision making across the company. Prior to joining BioCryst in 2015, she served as the Senior Director of Global Business Intelligence and Customer Insight at United Therapeutics. Prior to that, she spent 3 years in marketing and market analytics roles at Talecris Biotherapeutics (now Grifols) and 5 years in various marketing research roles at Novartis. Ms. Rosselli holds a B.S. in Cognitive and Behavioral Psychology from Duke University and a Master’s Degree in Public Health from the Yale University School of Medicine. She is a Fulbright Scholar and Presidential Leadership Scholar and currently serves on the Board of Directors of two nonprofit organizations: Triangle Residential Options for Substance Abusers and the Durham Medical Orchestra Foundation.
Chief Development Officer & Interim Chief Medical Officer
Chief Development Officer & Interim Chief Medical Officer
About William
Dr. Sheridan joined BioCryst in July 2008 following a 15-year tenure at Amgen. While at Amgen, he organized and led the company’s Medical Affairs functions in the United States and Europe, making significant contributions to the successful launch of many compounds. Dr. Sheridan organized the Global Health Economics and Outcomes Research function, supervised product development team leaders, and led several clinical development-phase PDTs. Dr. Sheridan earned his M.B. B.S. degree (M.D.-equivalent) at the University of Melbourne in Victoria, Australia He is a board-certified fellow of the Royal Australasian College of Physicians, with a subspecialty in medical oncology, and a fellow of the American College of Physicians.
President, Chief Executive Officer
President, Chief Executive Officer
About Jon
Jon P. Stonehouse joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the company, he served as Senior Vice President of Corporate Development for Merck KGaA, where his responsibilities included corporate mergers and acquisitions, global licensing and business development, as well as corporate strategy and alliance management. Mr. Stonehouse was responsible for leading the effort to develop a strategy for Merck KGaA that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra Merck/AstraZeneca. He began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck & Co., Inc. Mr. Stonehouse earned his B.S. in Microbiology at the University of Minnesota.
Chief Research & Development Officer
Chief Research & Development Officer
About Helen
Dr. Thackray is the Chief Research and Development Officer for BioCryst. Prior to joining the company, she was the Chief Medical Officer and Senior Vice President of Clinical Development at GlycoMimetics, Inc., where she led their orphan product, fast-track, and breakthrough therapy programs in rare diseases and oncology. Previous experience includes a senior role in clinical development at Biosynexus, and over a decade on the Research Ethics Review Board of the National Center for Healthcare Statistics, part of the Centers for Disease Control and Prevention. She is a board-certified pediatrician, serving on the faculty of the Children’s National Medical Center and George Washington University School of Medicine and Health Sciences from 2000 to present. Dr. Thackray holds a B.S. in Biological Sciences from Stanford University, an M.D. from the George Washington University School of Medicine and Health Sciences, and has authored more than 60 peer-reviewed articles and presentations. She completed her pediatric residency and chief residency at Children’s National Medical Center, trained in medical genetics at the National Human Genome Research Institute at the National Institutes of Health, and is a fellow of the American Academy of Pediatrics.
Guiding our path forward
With strong governance and insight from many decades of industry experience, our distinguished Board of Directors provides us with the counsel and support to help advance our program and business objectives with urgency and purpose.
Nancy Hutson, PhD
Chair of the Board
Dr. Hutson was appointed to the Board in January 2012, and was elected Chair of the Board in March 2023. She brings over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer, Inc., in 2006 after spending 25 years in several research and leadership positions, most recently serving as Senior Vice President of Global Research & Development (R&D) as well as director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories. Dr. Hutson currently serves on the board of directors for Clearside Biomedical, Inc., Endo International plc., and PhaseBio Pharmaceuticals, Inc. She received a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. in physiology from Vanderbilt University.
George B. Abercrombie
George B. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. He served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible for leading operations in both the United States and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the pharmaceuticals division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc., as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, US commercial operations. Prior to joining Glaxo, he spent over 10 years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management, and business development.
Mr. Abercrombie began his career as a pharmacist after receiving a Bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill and later earned an MBA from Harvard University. Mr. Abercrombie served as Senior Vice President and Chief Commercial Officer at Innoviva, Inc. from June 2014 until September 2018. He currently serves as an adjunct professor at Duke University’s Fuqua School of Business, a board member of the North Carolina GlaxoSmithKline Foundation, an inaugural member of the Duke University Psychiatry and Behavioral Sciences Advisory Board, a member of the North Carolina Board of Science, Technology, and Innovation, and the Chief Executive Officer of Abercrombie Advisors LLC. Mr. Abercrombie’s executive experience in the pharmaceutical industry and management positions with major pharmaceutical companies provide an excellent background for service on the board.
Steve Aselage
Steve Aselage was appointed to the Board in January 2019. Mr. Aselage most recently served as Chief Executive Officer of Travere Therapeutics, a biopharmaceutical company specializing in identifying, developing, and delivering life-changing therapies to people living with rare diseases, which he joined in 2012. He has more than 40 years of experience in the biopharmaceutical industry, including substantial rare disease, commercial, and business development experience. From 2005 to 2012, Mr. Aselage served as Executive Vice President and Chief Business Officer of BioMarin. Prior to BioMarin, Mr. Aselage held positions of increasing responsibility at a number of companies, including Bristol Laboratories, Genentech, and Sangstat. He continues to serve as chairman of Acer Therapeutics and on the advisory council of the University of Notre Dame Department of Science.
Steven Galson, MD, MPH
Dr. Galson was appointed to the Board in September 2021. Most recently, Dr. Galson served as the Senior Vice President, Research and Development at Amgen. Prior to joining Amgen in 2010, where he also led regulatory affairs, Dr. Galson spent more than 20 years in public service roles across the US Department of Health and Human Services, Department of Energy, Environmental Protection Agency, and Centers for Disease Control and Prevention. From 2001 to 2007, he progressed from Deputy Director to Acting Director to Director of the Center for Drug Evaluation and Research at the US Food and Drug Administration. From 2007 to 2009 he served as acting Surgeon General of the United States. Dr. Galson received a B.S. in biochemistry from the State University of New York at Stony Brook, an M.D. from the Mt. Sinai School of Medicine, and a master’s degree in public health from the Harvard School of Public Health.
Theresa Heggie
Theresa Heggie was appointed to the Board in December 2018, bringing more than 30 years of experience as a business leader in the pharmaceutical, biotechnology, and rare disease industries. Ms. Heggie most recently served as Chief Operating Officer of ProQR, a company developing RNA therapies for genetic eye diseases. Prior to joining ProQR in 2021, she was Chief Executive Officer of Freeline, and before that was Senior Vice President, Head of Europe, Middle East, and Africa, and Canada for Alnylam Pharmaceuticals, and Global Chief Strategy and Marketing Officer for Bupa. Ms. Heggie also served as Senior Vice President of global commercial operations for Shire Human Genetic Therapies (HGT).
Ms. Heggie joined Shire in 2005 as part of the acquisition of TKT where she was responsible for HGT’s business in Europe, Middle East, and Africa, and, following the acquisition of Jerini in 2008, was appointed Chief Executive Officer of Jerini AG based in Berlin. Prior to joining Shire, Ms. Heggie spent more than 20 years in the pharmaceutical industry with Janssen Pharmaceuticals, Ohmeda Pharmaceutical Products Division (part of BOC), and Baxter in marketing, sales, and clinical research roles. Ms. Heggie received her B.S. from Cornell University.
Alan G. Levin
Alan G. Levin was appointed to the Board in February 2020. In addition to his 20-year career at Pfizer, where he served as Chief Financial Officer, Mr. Levin served as Chief Financial Officer of Endo Pharmaceuticals, Inc. over a five-year period where the company experienced a nearly 400 percent increase in its market capitalization. He currently serves on the board of directors of Diffusion Pharmaceuticals, Inc., a development-stage company focused on therapeutics to enhance the effectiveness of treatments for stroke and cancer, and on the advisory board of Auven Therapeutics, a global private equity fund that acquires and pursues accelerated development of breakthrough therapeutic drugs, prior to licensing them to commercial partners.
From 2013 through 2019, Mr. Levin served on the board of directors of Aceto Corporation, a multinational company involved in the sale and distribution of generic drugs, pharmaceutical intermediates, and performance chemicals. He also serves on the board of directors of the Critical Path Institute, a nonprofit collaboration between the US Food and Drug Administration and the pharmaceutical industry, focused on streamlining and accelerating the development and regulatory pathways for innovative medicines. Mr. Levin is an audit committee financial expert, as defined by the Securities and Exchange Commission, and is a certified public accountant. He holds a Bachelor’s degree from Princeton University and a Master’s degree from New York University’s Stern School of Business.
Amy McKee, M.D.
Dr. McKee was appointed to the Board in September 2021. Dr. McKee currently serves as Chief Medical Officer and Global Head, Oncology Center of Excellence for Parexel, a leading global clinical research organization. Prior to joining Parexel in 2019, Dr. McKee spent more than a decade at the US Food and Drug Administration (FDA) in leadership roles of increasing responsibility. She served as a primary reviewer of new drug applications (NDAs) and biologics license applications (BLAs) across multiple divisions and served as both the acting Deputy Director and supervisory Associate Director of the Office of Hematology and Oncology Products where she managed four separate divisions performing NDA and BLA reviews. From January 2018 through February 2019, Dr. McKee was the deputy Center Director for the FDA’s Oncology Center of Excellence, which helps expedite development of innovative medical products for oncologic and hematologic malignancies and supports an integrated approach to their clinical evaluation. Dr. McKee received a B.A. in Russian and East European studies from Middlebury College and received her M.D. from Tulane University School of Medicine. She was a clinical fellow at the National Cancer Institute/Johns Hopkins University in the pediatric hematology/oncology fellowship program.
Vincent Milano
Vincent Milano was appointed to the Board in July 2021. Mr. Milano has over 25 years of rare disease leadership experience. He most recently served as Chief Executive Officer of Idera Pharmaceuticals, Inc., and previously served as Chairman, President, and Chief Executive Officer of ViroPharma, which successfully developed and launched Cinryze for the treatment of HAE in the United States and Europe, prior to its acquisition by Shire in 2014. Before joining ViroPharma in 1996, he served as a Senior Manager at KPMG LLP, an independent registered public accounting firm. Mr. Milano currently serves on the board of directors of Aclaris Therapeutics and is the chairman of the board of Aceragen, Inc. (previously Idera Pharmaceuticals) and Life Science Cares Philadelphia. He received his B.S. in accounting from Rider College.
Machelle Sanders
Machelle Sanders was appointed to the Board of directors in February 2022. She currently serves as North Carolina Secretary of Commerce. Ms. Sanders has over 30 years of pharmaceutical and biotechnology experience with increasing levels of quality assurance and manufacturing operations responsibilities with Biogen, Purdue Pharmaceuticals, and AkzoNobel. Most recently, she led product operations for Biogen’s $8 billion multiple sclerosis franchise and was Vice President of manufacturing and General Manager for Biogen’s 1200-employee Research Triangle Park facility, the company’s largest global manufacturing operation. Prior to being appointed as North Carolina’s Secretary of Commerce in February 2021, Ms. Sanders served as Secretary of the North Carolina Department of Administration from January 2017 until February 2021. Ms. Sanders currently serves on the board of directors of Novan. She received a B.S. in biochemistry from North Carolina State University and a Master’s in health administration from Pfeiffer University.
Jon P. Stonehouse
Jon P. Stonehouse joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA where his responsibilities included corporate mergers and acquisitions, global licensing and business development, as well as corporate strategy and alliance management. Mr. Stonehouse was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra Merck/AstraZeneca. Mr. Stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck & Co., Inc. In 2011, Mr. Stonehouse joined the advisory board of Genscript, a private bioservices company. In December 2014, he joined the Board of Directors of Bellicum Pharmaceuticals, Inc., a publicly traded clinical-stage biopharmaceutical company focused on novel cellular immunotherapies.
Mr. Stonehouse earned his B.S. in Microbiology at the University of Minnesota. As Chief Executive Officer and President of BioCryst, Mr. Stonehouse brings to the board an intimate knowledge of our business, and his executive experience in a variety of capacities at major pharmaceutical companies provides industry-specific operational experience that is beneficial to the board.
State regulations/
disclosures
California
California Compliance Program Declaration Download here >>
Colorado
Colorado WAC Disclosure for ORLADEYO (berotralstat) Download here >>
Connecticut
Connecticut WAC Disclosure for ORLADEYO (berotralstat) Download here >>
Vermont
Vermont AWP Disclosure for ORLADEYO (berotralstat)